Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors, discusses changes to Medicare Part D expected to come in 2020 and their implications.
Crescent Moore, PharmD, PhD, BCPS, senior consultant, BluePeak Advisors, discusses changes to Medicare Part D expected to come in 2020 and their implications.
Transcript
What changes to Medicare Part D should we expect to see in the coming year, and what will their implications likely be?
For 2020, I definitely think we’ll continue to see plan sponsors continue their opioid efforts as it is a top priority not only for CMS but also for the administration. Additionally, I think we’re going to see more plans move into administering the Part B step therapy, especially since for 2019, the memo came out a little late in the year for plans to really be able to jump on it quickly, and additionally with us having some more guidance coming this year, I think plans will definitely be ready for it for 2020. Indication-based formularies, I think it it’s not necessarily going to be a big, widespread adoption. I think we’re going to see plan sponsors maybe pilot it in a few therapeutic areas to really just see how it goes, how hard or how easy it is to administer, but at the end of the day, I think what we’re all trying to move towards and what we’re really hoping to see is some lower drug costs and better outcomes for our members.
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More